We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
By clicking "Allow All" you agree to the storing of cookies on your device to enhance site navigation, analyse site usage and support us in providing free open access scientific content. More info.
Owlstone Medical is developing a breathalyzer with a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.
The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award winning ReCIVA Breath Sampler ensures reliable collection of breath samples.
Breath Biopsy is supporting research into early detection and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.
Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection
Owlstone Medical launches OMED Health to enable patients to better understand their gut microbiome and manage their digestive health
Owlstone Medical Publishes Data on the Use of Exhaled Volatile Organic Compounds as Biomarkers for Liver Disease Detection
Owlstone Medical Presents Breath Biopsy® VOC Atlas
Reviewing breath biomarkers for inflammatory respiratory diseases
Every breath counts; Utilizing breath biopsy technology to detect disease early
Breath Biopsy®: The Complete Guide